EMD 640744

Drug Profile

EMD 640744

Alternative Names: DPX-Survivac; EMD-640744; Survivac

Latest Information Update: 31 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck Serono
  • Developer Immunovaccine; Merck Serono
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 31 May 2017 Immunovaccine terminates phase II trial for Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in Canada
  • 16 May 2017 Efficacy data from a phase II trial in Diffuse large B-cell lymphoma released by Immunovaccine
  • 16 May 2017 Immunovaccine plans a phase II trial for Diffuse large B-cell lymphoma (Combination therapy, Recurrent, Second-line therapy or greater) in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top